OnKure, Inc. and the University of Colorado Cancer Center today announced enrollment of the first patient in a first-in-human phase 1 clinical trial testing investigational anti-cancer agent OKI-179, a novel and Class-selective HDAC inhibitor, in patients with...
Takeda has stopped the phase III TOURMALINE-AL1 clinical trial in patients with relapsed or refractory AL amyloidosis because treatment with NINLARO (ixazomib) in combination with dexamethasone did not demonstrate a significant improvement in overall hematologic...
A US-based pharmaceutical company, Aerpio Pharmaceuticals, Inc., recently announced the initiation of Phase 1b clinical trial of AKB-9778 to develop treatment of PAOG (primary open angle glaucoma), report sources. For the record, Aerpio Pharmaceuticals is a...
Parexel, a leader in the development of innovative new therapies to improve the world’s health, today announced a strategic partnership with CLARINESS, a leading global patient recruitment company, to further accelerate clinical trial recruitment and patient...
Rituxan met the primary and secondary endpoints in the Phase III PEMPHIX study Rituxan was the first and only biologic therapy approved by the FDA in June 2018 for the treatment of pemphigus vulgaris based on results from the Ritux 3 clinical trial Results will be...
Intensive urate-lowering strategy may protect against the progression of diabetic kidney disease Madrid, Spain, 13 June 2019: The results of a phase IIa clinical trial presented today at the Annual European Congress of Rheumatology (EULAR 2019) demonstrate a rapid...
Email
Text